MedPageToday
MedPage Today) — A monoclonal antibody targeting a novel migraine prevention pathway showed success in the phase II HOPE trial.
A single 750 mg intravenous infusion of investigational Lu AG09222 bested placebo in reducing migraine frequency…
Read More
Novel Agent Reduces Monthly Migraine Days
MedPage Today) — A monoclonal antibody targeting a novel migraine prevention pathway showed success in the phase II HOPE trial. A single 750 mg intravenous infusion of investigational Lu AG09222 bested placebo in reducing migraine frequency…